The immune system and COVID-19: Friend or foe?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5
Hanaei, 2020, COVID-19: Developing from an Outbreak to A Pandemic, Arch. Med. Res., 10.1016/j.arcmed.2020.04.021
Recalcati, 2020, Cutaneous manifestations in COVID-19: a first perspective, J. Eur. Acad. Dermatol. Venereol.
Giamarellos-Bourboulis, 2020, Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure, Cell Host Microbe, 10.1016/j.chom.2020.04.009
Di Gennaro, 2020, Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review, Int. J. Environ. Res. Public Health, 17, 10.3390/ijerph17082690
Jahanshahlu, 2020, Central Nervous System Involvement in COVID-19 [published online ahead of print, 2020 May 22], Arch. Med. Res.
Infantino, 2020, Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives, Isr. Med. Assoc. J., 22, 203
Jia, 2005, ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia, J. Virol., 79, 14614, 10.1128/JVI.79.23.14614-14621.2005
Rezaei, 2020, COVID-19 affects healthy pediatricians more than pediatric patients, Infect. Control Hosp. Epidemiol., 1, 10.1017/ice.2020.139
Tipnis, 2000, A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase, J. Biol. Chem., 275, 33238, 10.1074/jbc.M002615200
Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, 507, 10.1016/S0140-6736(20)30211-7
Saghazadeh, 2020, Immune-epidemiological parameters of the novel coronavirus - a perspective, Expert. Rev. Clin. Immunol., 16, 465, 10.1080/1744666X.2020.1750954
Yuan, 2020
Fung, 2020, A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses, Emerg Microbes Infect, 9, 558, 10.1080/22221751.2020.1736644
Hamming, 2004, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol., 203, 631, 10.1002/path.1570
Li, 2020, Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19, J. Autoimmun., 102463, 10.1016/j.jaut.2020.102463
Li, 2020, Molecular immune pathogenesis and diagnosis of COVID-19, J Pharm Anal., 10, 102, 10.1016/j.jpha.2020.03.001
Groeneveld, 2002, Vascular pharmacology of acute lung injury and acute respiratory distress syndrome, Vasc. Pharmacol., 39, 247, 10.1016/S1537-1891(03)00013-2
Rokni, 2020, Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS, Rev. Med. Virol., 30, 10.1002/rmv.2107
Prompetchara, 2020, Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic, Asian Pac. J. Allergy Immunol., 38, 1
Barnes, 2020, Targeting potential drivers of COVID-19: neutrophil extracellular traps, J. Exp. Med., 217, 10.1084/jem.20200652
Casillo, 2020, Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?, Pharmacol. Res., 104791, 10.1016/j.phrs.2020.104791
Chiappelli, 2020, CoViD-19 Immunopathology & Immunotherapy, Bioinformation, 16, 219, 10.6026/97320630016219
Diao, 2020
Zhang, 2020, The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality, Int. J. Antimicrob. Agents, 105954, 10.1016/j.ijantimicag.2020.105954
Lin, 2020, Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia, Emerging Microbes & Infections, 9, 727, 10.1080/22221751.2020.1746199
Fathi, 2020, Lymphopenia in COVID-19: Therapeutic opportunities, Cell Biol. Int., 1
Spezzani, 2020, Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple, Swiss Med. Wkly., 10.4414/smw.2020.20246
Gianfrancesco, 2020, Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries [published online ahead of print, 2020 Apr 16], Lancet Rheumatol., 2, e250, 10.1016/S2665-9913(20)30095-3
Russell, 2020, Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence, Ecancermedicalscience, 14, 1022, 10.3332/ecancer.2020.1022
Henderson, 2020, On the Alert for Cytokine Storm: Immunopathology in COVID -19, Arthritis Rheum., 10.1002/art.41285
Liu, 2020, Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?, J. Autoimmun., 102452, 10.1016/j.jaut.2020.102452
Wang, 2020, Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis, Research (Wash D C), 2020, 2402961
Guzman-Flores, 2012, Cells of innate and adaptive immunity in type 2 diabetes and obesity, Gac. Med. Mex., 148, 381
Meshkani, 2016, Tissue resident macrophages: key players in the pathogenesis of type 2 diabetes and its complications, Clin. Chim. Acta, 462, 77, 10.1016/j.cca.2016.08.015
Yang, 2010, Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes, Acta Diabetol., 47, 193, 10.1007/s00592-009-0109-4
Guo, 2020, Diabetes is a risk factor for the progression and prognosis of COVID-19, Diabetes Metab. Res. Rev., 10.1002/dmrr.3319
Ulrich, 2020, CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement, Stem Cell Rev. Rep., 16, 434, 10.1007/s12015-020-09976-7
Wang, 2020, SARS-CoV-2 invades host cells via a novel route: CD147-spike protein, bioRxiv, 988345
Wan, 2020, Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients, Br. J. Haematol., 189, 428, 10.1111/bjh.16659
Liu, 2020
Tufan, 2020, COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs, Turkish Journal of Medical Sciences, 50, 620, 10.3906/sag-2004-168
Wu, 2020, TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib [published online ahead of print, 2020 Mar 11], J Microbiol Immunol Infect., 53, 368, 10.1016/j.jmii.2020.03.005
Li, 2020, Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan, J. Allergy Clin. Immunol., 10.1016/j.jaci.2020.04.006
McGonagle, 2020, The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease, Autoimmun. Rev., 102537, 10.1016/j.autrev.2020.102537
Saghazadeh, 2020, Towards treatment planning of COVID-19: rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroids, Int. Immunopharmacol., 84, 1
Stadlbauer, 2020, SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup, Current Protocols in Microbiology, 57, 10.1002/cpmc.100
Ju, 2020
Md Insiat Islam, 2020, Current drugs with potential for treatment of COVID-19: a literature review, J Pharm Pharm Sci, 23, 58, 10.18433/jpps31002
Bloch, 2020, Deployment of convalescent plasma for the prevention and treatment of COVID-19, J. Clin. Invest., 130, 2757, 10.1172/JCI138745
Jawhara, 2020, Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients?, Int. J. Mol. Sci., 21, 2272, 10.3390/ijms21072272
Roback, 2020, Convalescent Plasma to Treat COVID-19: Possibilities and Challenges, JAMA, 10.1001/jama.2020.4940
Teixeira da Silva, 2020, Convalescent plasma: A possible treatment of COVID-19 in India [published online ahead of print, 2020 Apr 15], Med J Armed Forces India, 76, 236, 10.1016/j.mjafi.2020.04.006
Ye, 2020, Treatment with convalescent plasma for COVID-19 patients in Wuhan, China, J. Med. Virol., 10.1002/jmv.25882
Wang, 2020, A human monoclonal antibody blocking SARS-CoV-2 infection, Nat. Commun., 11, 2251, 10.1038/s41467-020-16256-y
Mohamed, 2020, Borderless collaboration is needed for COVID-19-A disease that knows no borders, Infect. Control Hosp. Epidemiol., 1, 10.1017/ice.2020.162
Pawelec, 2020, Can an effective SARS-CoV-2 vaccine be developed for the older population?, Immun. Ageing, 17, 10.1186/s12979-020-00180-2
Zhang, 2020, Progress and prospects on vaccine development against SARS-CoV-2, Vaccines, 8, 153, 10.3390/vaccines8020153